Keuangan CVS Health Corporation (CVS)
NYSE · Healthcare · Medical - Healthcare Plans · Karyawan: 259.500 · CEO: J. David Joyner
- Harga
- $90,25 -0,09%
- Kapitalisasi pasar
- $115 M
- Nilai perusahaan
- $180 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-05
- Laporan berikutnya
- 2026-11-04 Estimasi EPS: $1,65
Pendapatan (TTM)$415 M+7,4% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)2,0%-0,3 poin vs tahun laluLaba operasional: $8,29 M
Laba bersih (TTM)$4,91 M+8,3% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$11,8 M+146,0% vs tahun laluCapex: $3,02 M
EPS dilusian (TTM)$3,78+5,6% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$62,3 M+9,0% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $115 M EV $180 M
- Pendapatan
- $415 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +4% Konsensus FY2026
- Margin laba
- 1,2% Laba bersih / pendapatan, TTM
- P/E
- 23,6× Forward 11,2× (FY2026)
- P/S
- 0,3× Harga / penjualan, TTM
- EV / EBITDA
- 13,5× TTM
- Arus kas bebas
- $11,8 M 12 bulan terakhir
- Laba bersih
- $4,91 M 12 bulan terakhir
- Estimasi pendapatan
- $417 M Konsensus FY2026
- Laba
- 2026-11-04 Estimasi pendapatan: $105 M
- Dividen
- $2,66 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-05): pendapatan melampaui 6,1%, EPS melampaui 39,5%Pendapatan $106 M vs $100 M yang diharapkan (+6,1%); EPS $2,58 vs $1,85 (+39,5%).
- Pertumbuhan pendapatan stabil: 7,3% yoyPendapatan Q2 '26: $106 M, rata-rata empat kuartal sebelumnya: 7,6%.
- Margin operasional 2,0% (TTM), dibanding tahun lalu: -0,3 poinLaba operasional tumbuh -7,4%, pendapatan tumbuh 7,4%.
- 43,2% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $5,79 M vs laba operasional $8,29 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 0,7% dari pendapatan (tahun lalu 0,7%)$3,02 M diinvestasikan dalam 4 kuartal terakhir (+8,4% dibanding tahun sebelumnya). Arus kas bebas: $11,8 M = 239,7% dari laba bersih.
- $3,42 M dikembalikan ke pemegang saham = 29,1% dari arus kas bebasBuyback: $0 (tahun lalu -$1 jt), dividen: $3,42 M, kompensasi saham: $316 jt (TTM).
- Jumlah saham dilusian naik dalam setahun: 1,0%Saham dilusian pada Q2 '26: 1,28 M, setahun sebelumnya: 1,27 M.
- Utang neto: $62,3 MKas + investasi jangka pendek: $14 M, utang termasuk sewa: $76,3 M; tahun lalu utang neto: $68,6 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $106 M | $98,9 M | +7,3% |
| Margin kotor | 14,8% | 13,7% | +1,1 poin |
| Laba operasional | $4,7 M | $2,38 M | +97,5% |
| Margin operasional | 4,4% | 2,4% | +2,0 poin |
| Laba bersih | $3 M | $1,02 M | +193,3% |
| EPS dilusian | $2,31 | $0,80 | +188,7% |
| Arus kas operasional | $6,35 M | $1,9 M | +234,5% |
| Capex | $691 jt | $607 jt | +13,8% |
| Arus kas bebas | $5,65 M | $1,29 M | +338,3% |
| R&D | $0 | $0 | – |
| Kompensasi berbasis saham | $176 jt | $136 jt | +29,4% |
Dilaporkan vs konsensus
2026-08-05| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $106 M | $100 M | +6,1% |
| EPS (basis konsensus) | $2,58 | $1,85 | +39,5% |
Dari laporan 2026-08-05 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Pharmacy Revenue | $60,8 M | +9,9% | 59,4% | $239 M | +9,2% | |
| Premiums | $35,1 M | +2,7% | 34,3% | $137 M | +6,0% | |
| Front Store Revenue | $5,41 M | +0,7% | 5,3% | $21,5 M | +0,1% | |
| Product and Service, Other | $1,04 M | -70,5% | 1,0% | $5,93 M | -61,1% | |
| Corporate And Other Segment | – | – | – | – | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $14,8 M
- Capex
- -$3,02 M
- Buyback
- $0
- Dividen
- -$3,42 M
- Akuisisi
- $123 jt
- Utang neto diterbitkan
- -$5,23 M
- Kompensasi berbasis saham
- $316 jt
- Arus kas bebas
- $11,8 M
- Dikembalikan ke pemegang saham / FCF
- 29,1%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 23,6× | 25,3× | 12,2× – 56,7× |
| EV / EBITDA | 13,5× | 12,8× | 9,5× – 18,8× |
| EV / Penjualan | 0,4× | 0,5× | 0,4× – 0,7× |
| Harga / FCF | 9,8× | 9,9× | 8,6× – 12,9× |
| Harga / Nilai buku | 1,4× | 1,4× | 0,7× – 1,8× |
| Imbal hasil FCF | 10,2% | 10,4% | 7,8% – 11,6% |
| Imbal hasil modal yang diinvestasikan | 4,1% | 4,7% | 3,6% – 5,9% |
| Imbal hasil ekuitas | 6,4% | 7,2% | 2,4% – 10,9% |
Analis
Target konsensus $111,25 (+23,3%)
rentang $92,00 – $123,00 · peringkat Buy
Beli kuat2
Beli33
Tahan6
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $417 M | +3,7% | $8,05 | +479,1% | 11,2× | 17 |
| FY2027 | $430 M | +3,0% | $8,53 | +5,9% | 10,6× | 18 |
| FY2028 | $449 M | +4,5% | $9,70 | +13,8% | 9,3× | 13 |
| FY2029 | $475 M | +5,6% | $10,84 | +11,7% | 8,3× | 10 |
| FY2030 | $492 M | +3,6% | $11,75 | +8,4% | 7,7× | 5 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 356 angka yang ditandai CVS Health Corp. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Trade, Current | $17,2 M | $17,3 M | -0,5% | $17,6 M | $15,9 M | +11,0% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $40,3 M | $40,7 M | -0,8% | $39,8 M | $36,5 M | +9,1% |
| Accounts Receivable, Allowance for Credit Loss | $169 jt | $374 jt | -54,8% | $182 jt | $407 jt | -55,3% |
| Accrued Liabilities, Current | $22,5 M | $23,1 M | -2,7% | $22,4 M | $20,8 M | +7,6% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $188 jt | $272 jt | -30,9% | $406 jt | -$120 jt | +438,3% |
| Advertising Expense | – | – | – | $970 jt | $989 jt | -1,9% |
| Amortization of Intangible Assets | $431 jt | $494 jt | -12,8% | $1,98 M | $2,03 M | -2,4% |
| AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax | $17 jt | $30 jt | -43,3% | $20 jt | $1 jt | +1.900,0% |
| Asset Impairment Charges | – | – | – | $152 jt2023-12-31 | – | – |
| Assets | $254 M | $258 M | -1,8% | $254 M | $253 M | +0,1% |
| Assets Held by Insurance Regulators | $737 jt2025-12-31 | $713 jt | +3,4% | $737 jt | $713 jt | +3,4% |
| Assets, Current | $75,3 M | $75,6 M | -0,4% | $74,7 M | $68,6 M | +8,8% |
| Assets, Fair Value Disclosure | $41,1 M | – | – | $37,5 M | $35 M | +7,2% |
| Assumed Premiums Earned | – | – | – | $573 jt | $471 jt | +21,7% |
| Business Combination, Integration Related Costs | $10 jt | $28 jt | -64,3% | $117 jt | $243 jt | -51,9% |
| Cash and Cash Equivalents, at Carrying Value | $11,3 M | $11,8 M | -3,9% | $8,45 M | $8,59 M | -1,5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $11,3 M | – | – | $8,45 M | $8,59 M | -1,5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $11,5 M | $12 M | -4,1% | $8,71 M | $8,88 M | -1,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $1,77 M | $1,68 M | +5,3% | -$172 jt | $359 jt | -147,9% |
| Ceded Premiums Earned | – | – | – | $1,31 M | $1,2 M | +8,7% |
| Commercial Paper | $02025-12-31 | $2,12 M | -100,0% | $0 | $2,12 M | -100,0% |
| Common Stock, Dividends, Per Share, Declared | $0,67 | $0,67 | 0,0% | $2,66 | $2,66 | 0,0% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 3,2 M | 3,2 M | 0,0% | 3,2 M | 3,2 M | 0,0% |
| Common Stock, Shares, Issued | 1,8 M | 1,79 M | +0,6% | 1,79 M | 1,78 M | +0,5% |
| Common Stock, Shares, Outstanding | 1,28 M | 1,27 M | +0,9% | 1,27 M | 1,26 M | +0,9% |
| Common Stock, Value, Issued | $18 jt2025-09-30 | $18 jt | 0,0% | $18 jt2024-12-31 | $18 jt | 0,0% |
| Common Stocks, Including Additional Paid in Capital | $51 M | $50 M | +1,9% | $50,4 M | $49,7 M | +1,5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $16 jt | -$8 jt | +300,0% | -$40 jt | -$28 jt | -42,9% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $2,97 M | $1,23 M | +140,4% | $2,29 M | $4,79 M | -52,1% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $2,98 M | $1,23 M | +143,2% | $2,25 M | $4,76 M | -52,7% |
| Contract with Customer, Asset, after Allowance for Credit Loss, Current | $13 M | $10,5 M | +24,1% | $10,6 M | $9,88 M | +6,9% |
| Contract with Customer, Liability, Current | $62 jt2025-12-31 | $144 jt | -56,9% | $62 jt | $144 jt | -56,9% |
| Cost of Goods and Services Sold | $58,9 M | $54 M | +9,0% | $221 M | $206 M | +7,2% |
| Costs and Expenses | $101 M | $96,5 M | +5,0% | $397 M | $364 M | +9,1% |
| Current Federal Tax Expense (Benefit) | – | – | – | -$217 jt | $1,62 M | -113,4% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $114 jt | $36 jt | +216,7% |
| Current Income Tax Expense (Benefit) | – | – | – | $306 jt | $2,13 M | -85,7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $409 jt | $476 jt | -14,1% |
| Current Year Claims and Claims Adjustment Expense | $31,6 M | $31,1 M | +1,6% | $127 M | $116 M | +9,9% |
| Debt and Lease Obligation | $64,6 M2025-12-31 | $66,3 M | -2,6% | $64,6 M | $66,3 M | -2,6% |
| Debt Instrument, Unamortized Premium | $156 jt2025-12-31 | $170 jt | -8,2% | $156 jt | $170 jt | -8,2% |
| Debt Securities, Available-for-sale | $29,3 M | $26,6 M | +10,5% | $28,7 M | $26 M | +10,3% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $207 jt | $347 jt | -40,3% | $449 jt | $178 jt | +152,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $422 jt | $449 jt | -6,0% | $331 jt | $707 jt | -53,2% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $3,14 M | $2,75 M | +14,1% | $2,99 M | $3,16 M | -5,4% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $5,9 M | $4,53 M | +30,1% | $5,3 M | $4,68 M | +13,1% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $11,7 M | $11 M | +6,8% | $11,5 M | $10,6 M | +8,9% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $1,17 M | $961 jt | +21,2% | $815 jt | $763 jt | +6,8% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $2,48 M | $4,14 M | -40,2% | $3,48 M | $5,73 M | -39,4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | $281 jt | $396 jt | -29,0% | $301 jt | $580 jt | -48,1% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | 1.831 security | 3.068 security | -40,3% | 2.465 security | 4.174 security | -40,9% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $12,3 M | $2,51 M | +391,9% | $2,86 M | $7,51 M | -62,0% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | $141 jt | $53 jt | +166,0% | $30 jt | $127 jt | -76,4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | 6.098 security | 1.528 security | +299,1% | 1.578 security | 4.502 security | -64,9% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $2,98 M | $2,56 M | +16,3% | $2,85 M | $2,91 M | -2,1% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $5,88 M | $4,56 M | +28,8% | $5,38 M | $4,58 M | +17,6% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $11,8 M | $11,1 M | +6,2% | $11,7 M | $10,5 M | +11,3% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $1,17 M | $963 jt | +21,3% | $817 jt | $761 jt | +7,4% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01